ena-STUDY-CAMBRIDGE INSTITUTE - CANCER RESEARCH UK AND UNIVERSITY OF CAMBRIDGE-17-05-2018-16:26:09:324-152
Expression changes in BRCA1-deficient breast cancer PDX models treated with PARP-inhibitors.
BRCA1 deficiencies cause breast, ovarian and other cancers, and render tumours hypersensitive to PARP-inhibitors. To understand resistance mechanisms, we conducted explored expression changes in BRCA1-deficient breast cancer PDX models treated with PARP-inhibitors.
BRCA1 deficiencies cause breast, ovarian and other cancers, and render tumours hypersensitive to PARP-inhibitors. To understand resistance mechanisms, we conducted explored expression changes in BRCA1-deficient breast cancer PDX models treated with PARP-inhibitors.